Empyrean Capital Partners’s Supernova Partners Acquisition Company III, Ltd. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 STRE.WS Stock Holding History
Bought
Maintained
Sold
Other funds holding STRE.WS
RCM
SC
HCM
PC
FTCM
PSAMP
QGA
CCP
FCM
BCM
Empyrean Capital Partners's STRE.WS Position: Q2 2022 in Review
Empyrean Capital Partners sold out of Supernova Partners Acquisition Company III, Ltd. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 (STRE.WS) in Q2 2022, closing a stake of 200,000 shares — an estimated $92K sold.
Empyrean Capital Partners first reported a position in STRE.WS in Q3 2021 and held it in 3 quarters. The position peaked at $184K in Q3 2021. 31 funds tracked by Wall St. Rank hold STRE.WS as of Q2 2022.
- Empyrean Capital Partners reported no remaining Supernova Partners Acquisition Company III, Ltd. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position as of Q2 2022 after selling out during the quarter.
- Empyrean Capital Partners sold 200,000 Supernova Partners Acquisition Company III, Ltd. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 shares in Q2 2022, an estimated $92K.
- Empyrean Capital Partners first reported a position in Supernova Partners Acquisition Company III, Ltd. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 in Q3 2021 and held it in 3 quarters.
- Empyrean Capital Partners's Supernova Partners Acquisition Company III, Ltd. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position peaked at $184K in Q3 2021.
- 31 funds tracked by Wall St. Rank held Supernova Partners Acquisition Company III, Ltd. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 as of Q2 2022.
Based on Empyrean Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.